Immunotherapy boosts chemo against rare sarcomas?

NCT ID NCT03719430

Completed Disease control Sponsor: Alexander Z. Wei, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and worked better than chemo alone. This is not a cure, but aims to better control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma leiomyosarcoma liposarcoma myxofibrosarcoma neurofibrosarcoma sarcoma soft tissue sarcoma synovial sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Columbia University Irving Medical Center/NYP

New York, New York, 10032, United States
Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.